

ALLEN & OVERY

Covid-19 coronavirus – the UK’s preparation for a vaccine

The UK Government has agreed supply deals for at least 340 million doses of six different vaccines, with most likely to require two doses. The vaccines are based on a range of vaccine technologies and are in various stages of clinical development.

Author: Megan McMellon

	Vaccine	Type	Status	Latest results	UK order
AstraZeneca and the University of Oxford	ChAdOx1 nCoV-19	Adenoviral vector vaccine	Late stage trials ongoing in the UK, Brazil and South Africa; Phase III trial in the US; planned trials in Japan and Russia	Phase I/II trial results indicated a T-cell response within 14 days and an antibody response within 28 days; immune response was stronger in participants who received two doses	100m doses
Johnson & Johnson (further information here)	JNJ-78436735 (also known as Ad26.COV2.S)	Adenoviral vector vaccine	Multiple-country Phase 3 studies ongoing for both single-dose regimen and two-dose regimen	Interim results from the Phase I/IIa study showed that a single dose induced a strong neutralising antibody response in nearly all participants	30m doses, with an option to acquire an additional 22m doses
Sanofi and GlaxoSmithKline	N/A	Adjuvanted protein-based vaccine	Phase I/II trial ongoing in the US, with first results due in December	Pre-clinical studies showed promising safety and immunogenicity	60m doses
Novavax (further information here and here)	NVX-CoV2373	Adjuvanted protein-based vaccine	Phase III trial ongoing in the UK; ongoing Phase II studies in South Africa, the US and Australia	Phase I results showed that the vaccine elicited robust antibody responses numerically superior to that seen in individuals who have recovered	60m doses
BioNTech and Pfizer	BNT162b2	mRNA-based vaccine	Ongoing multi-country Phase II/III studies	Interim results from Phase I/II studies in the US and Germany showed antibody as well as T-cell responses	30m doses
Valneva	VLA2001	Inactivated whole virus vaccine	Two-dose vaccine candidate scheduled to enter first clinical studies in December 2020	N/A	60m doses, with options over another 40m doses in 2020 and between 30m to 90m doses across 2023 to 2025